secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001297184-24-000055
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q3 2024 revenue up 5.9% to $191.2M; adjusted EPS down to $0.96
------------------------------------------------------------------------

- Net revenues $191.2M vs $180.6M in Q3 2023, up 5.9%.
- GAAP net income $40.4M ($0.78 diluted EPS) vs $49.2M ($0.91) year ago.
- Adjusted non-GAAP net income $49.6M ($0.96 diluted EPS) vs $61.9M ($1.15).
- Growth driven by BAQSIMI and Primatene MIST; Primatene on track for $100M annual sales.
- No updated guidance provided in the release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/0001297184-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718424000055/amph-20241106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer